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A series of b-amino alcohol tethered 4-aminoquinoline-isatin conjugates were synthesized with the aim
of probing their antimalarial structure activity relationship. Two of the most active conjugates (11b and
11f) exhibited antimalarial efficacy comparable to that of chloroquine, with IC50 values of 11.8 and
13.5 nM, respectively against chloroquine resistant W2 strain of Plasmodium falciparum and are devoid of
any cytotoxicity.
© 2014 Elsevier Masson SAS. All rights reserved.1. Introduction
With 207 million cases and 627 thousand deaths in 2012, ma-
laria is one of the world's deadliest diseases, affecting 64% of the
global population [1]. Plasmodium falciparum is the most virulent
human malaria parasite, and is responsible for most of the malaria-
related deaths [2,3]. Since the discovery of the natural product
quinine, many compounds with a quinoline scaffold have displayed
good antimalarial activity, leading to the development of effective
antimalarial agents, including chloroquine, amodiaquine, piper-
aquine and mefloquine [4e6]. Chloroquine has been extensively
utilized for decades because of its efficacy, safety and low cost.
However, the widespread resistance of P. falciparum to chloroquine
[2,7] has hampered efforts to combat malaria and led to the
development of the natural endoperoxide artemisinin and its
semisynthetic derivatives (artemether, artesunate, and dihy-
droartemisinin) as potent and fast acting antimalarials [8]. How-
ever, the worldwide deployment of artemisinin based combination
therapy is limited by relatively high cost of treatment, safety in
pregnancy and [9,10] early signs of resistance to artemisinin de-
rivatives in southeast Asia [11].
4-Aminoquinoline hybridization is now considered as an
attractive and viable strategy for developing new efficacious.
served.antimalarials and potentially delaying the emergence of drug
resistance [12e16]. The hybrid drug approach involves the rational
design of new chemical entities by covalent fusion of two phar-
macophores with complimentary activities and different pharma-
cological targets. The potential of a quinoline-hybridisation strategy
was demonstrated by several active antimalarials that include tri-
oxaferroquines [13], trioxaquines [17], an artemisinin-quinine
hybrid [18], 4-aminoquinoline based tetraoxanes [19], clotrima-
zole-based-4-aminoquinolines [20] and isatin-4-aminoquinoline
hybrids [21].
Isatin is one of the most promising heterocyclic scaffolds, with
anti-HIV [22], antiviral [23], anti-tumour [24e26], antifungal
[27,28], anti-angiogenic [29], anticonvulsant [30], and anti-Par-
kinson’s [31] activity. It is an effective SARS coronavirus 3CL pro-
tease inhibitor [32] and is well-tolerated in human subjects [33,34].
Isatin has major importance in organic synthesis due to a highly
reactive C-3 carbonyl group which allows easy transformation into
2-oxoindole compounds upon nucleophilic addition or spi-
roannulation [35]. 2-oxoindole derivatives such as SU-5416 (sem-
axanib) and SU-11248 (Sunitinib), a 5-fluoro-3-substituted-2-
oxoindole, were reported to have tyrosine kinase inhibitory and
anti-angiogenic properties [36,37]. The encouraging applications of
isatin in organic synthesis and its biological potential have
prompted efforts towards the synthesis and evaluation of novel
isatin-derivatives.
Recently the antimalarial potential of isatins via synthesis of
isatin-chalcone and isatin-thiolactone conjugates has been
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showed superior antimalarial activity; the most active scaffold
exhibited an IC50 of 6.92 mM against W2 strain of P. falciparum [39].
In particular, isatin-quinoline hybrids were shown to possess good
antiplasmodial profiles as evidenced by isatin-4-aminoquinolines
tethered via ethyl linker which exhibited IC50 values in the range
of 51e54 nM [21]. These examples suggested that the isatin-
quinoline core has an inherent potential as a lead antimalarial
agent and the introduction of substituents at appropriate positions
and the nature of linker in this structural framework could improve
its antimalarial efficacy.
A previous report from our group revealed the synthesis and
antimalarial evaluation of 1H-1,2,3-triazole-tethered-7-
chloroquinoline-isatin [40,41] and piperazine-tethered isatin-7-
chloroquinoline conjugates [42]. The observed activity profiles
among these conjugates were found to depend on the substituent
at the C-5 position of isatin and the length of the alkyl chain.
Building on our interest in molecular hybridization to develop new
antimalarials [43], we report herein the synthesis and biological
evaluation of hybrids containing a 4-aminoquinoline tethered to
isatin derivatives through an b-amino alcohol functionality. The
rationale behind the introduction of a b-amino alcohol linker is its
presence in a number of potent antimalarials, as exemplified by
mefloquine [44]. The length of the alkyl chain at the C-4 position of
the quinoline ring was varied because of its established impact on
antimalarial efficacy [45e48].
2. Results and discussion: synthetic chemistry and
pharmacology
2.1. Synthetic chemistry
The synthesis of the target b-amino alcohol tethered isatin-
quinoline hybrids involved an initial synthesis of the required
precursors viz. 1-oxiranylmethyl isatin 3 and 4-aminoquinolines 9
and 10. The procedure for the synthesis of 1-oxiranylmethyl indole-
2,3-dione 3was based on our recent report involving an initial base
promoted allylation of C-5 substituted isatins with its subsequent
epoxidation using m-chloroperbenzoic acid (mCPBA) in dry chlo-
roform at 60 C (Scheme 1) [49].
The preparation of 4 aminoquinoline-based precursors was
realized by heating 4,7-dichloroquinoline with an excess of
aliphatic chain/cyclic diaminoalkanes initially at 80 C and then at
135 C for 3 h, as shown in Scheme 2, [43a].
The target hybrids 11 were synthesized by refluxing precursors
3 and 9 in dry toluene at 110 C in the presence of a catalytic
amount of p-toluene sulphonic acid for 4e6 h. The conjugates 12
were prepared under similar conditions, however with longer
duration of refluxing (Scheme 3).
The purification of the reaction mixture via column chroma-
tography resulted in the isolation of desired structural chimeras 11
and 12. The structures were assigned on the basis of spectral data
and analytical evidence. The compound 11e, for example, analyzedN
H
O
O
Br
NaH, DMF,
60 oC, 6 hrs
R R
1 2
Scheme 1. Synthesis of 1-oxiranyas C23H23ClN4O3, showed a molecular ion peak at m/z 438.1451 in
its high resolution mass spectrum. The salient features of its 1H
NMR spectrum included the appearance of a pair of doublet of a
doublet at d 5.23 (J ¼ 1.4 and 10.3 Hz) corresponding to the eNCH2,
a multiplet at d 5.95 corresponding to the methine proton, and the
appearance of characteristic quinoline ring protons. The 13C NMR
spectrum showed characteristic absorptions at d 98.1 correspond-
ing to a methine carbon, while absorptions at d 152.1 and 171.0
corresponded to the presence of isatin carbonyls. The appearance of
methylene carbon at d 115.1, as confirmed by the 13C NMR (DEPT)
spectrum along with the requisite number of carbons, further
substantiated the assigned structures.
2.2. In vitro antiplasmodial activity
The synthesized compounds were evaluated for their anti-
malarial profiles against the CQ resistant W2 strain of P. falcipa-
rum (Table 1). The antimalarial activities depended upon the
nature of the substituent at the C-5 position of the isatin ring and
upon the alkyl chain length. Activities decreased as the chain
length was increased, from ethyl to propyl linker, except in the
case of 11b and 11f, which had essentially the same activity. A
further increase in chain length via introducing butyl and hexyl
linkers did not alter the observed antimalarial efficacy. The nature
of the substituent at the C-5 position of the isatin ring also seems
to play a crucial role in influencing antimalarial activity. The
presence of an inductively electron withdrawing chloro-
substituent at C-5 improved activity irrespective of the chain
length, with effects more pronounced with shorter (n ¼ 2,3) alkyl
chain lengths. The replacement of the chloro substituent with an
H, -CH3 or F group decreased activity, although few of these hy-
brids showed activity comparable with that of chloroquine, while
compound 11a (R ¼ H) showed better activity than chloroquine.
The replacement of the alkyl chain with a piperazine ring resulted
in a complete loss of activity, as evident with compounds 12bed.
Compounds 11b and 11f, with an optimum combination of
shorter alkyl chain lengths (n ¼ 2 and 3) and the presence of a
chloro-substituent at the C-5 position of th isatin ring, were the
most potent of the tested compounds, exhibiting IC50 of 11.8 and
13.5 nM, respectively. The most potent of the tested compounds
were then evaluated for their cytotoxic profiles against HCT116
(colon cancer cell line) cells at 0.2, 2.0 and 20 mM (Table 2). As
evident, the active conjugates were devoid of any cytotoxic ac-
tivity at low concentration and thus can act as therapeutic tem-
plates for the synthesis of new antimalarials.
In conclusion, the present manuscript describes the synthesis of
b-amino alcohol tethered isatin-4-aminoquinoline hybrids and
evaluation of their activities against P. falciparum. Our results reveal
a clear preference for shorter alkyl chain length (n ¼ 2,3) and the
presence of a chloro-substituent at the C-5 position of the isatin
ring for optimal antimalarial activity. The most potent and non-
cytotoxic conjugates exhibited antimalarial activity comparable to
that of chloroquine and artemisinin.N
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O
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Scheme 2. Synthesis of 4-aminoquinolines.
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Melting points were determined by open capillary using a Veego
Precision Digital Melting Point apparatus (MP-D) and are uncor-
rected. 1H NMR spectra were recorded in deuterochloroform and
DMSO-d6 with Jeol 300 (300 MHz) spectrometers using TMS as
internal standard. Chemical shift values are expressed as parts per
million downfield from TMS, and J values are in hertz. Splitting
patterns are indicated as s: singlet, d: doublet, t: triplet, m: multi-
plet, dd: double doublet, ddd: doublet of a doublet of a doublet, andScheme 3. Synthesis of isatin-4-br: broad peak. 13C NMR spectra were recorded on Jeol 300
(75 MHz) spectrometers in deuterochloroform and DMSO-d6 using
TMS as internal standard. High resolution mass spectra were
recorded on a Bruker-micrOTOF-Q II spectrometer. Column chro-
matography was performed on a silica gel (60e120 mesh).
3.1. Procedure for the synthesis of substituted N-allyl isatins 2
Isatin (1 mmol) was added to a stirred suspension of sodium
hydride (1.5mmol) in dry DMF (10mL) resulting in the formation ofaminoquinoline conjugates.
Table 1
Antimalarial activities of tested compounds against CQ resistant W2 strains of
P. falciparum.
Compound Structure IC50 (nM) clogP
11a 24.9 3.6
11b 11.7 4.5
11c ND 4.1
11d 488.1 3.9
11e 75.5 3.9
11f 13.5 4.8
11g 302.0 4.4
11h 72.3 4.2
11i 48.7 3.1
11j 101.0 4.0
11k 58.0 3.6
11l 45.3 3.3
11m 62.9 4.1
Table 1 (continued )
Compound Structure IC50 (nM) clogP
11n 49.7 5.0
11o 55.8 4.6
11p 59.6 4.4
12a 216.0 3.0
12b 1960.0 3.8
12c 1225.0 3.4
12d 1853.5 3.3
CQ 36.37
ART 04.37
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room temperature till the evolution of hydrogen ceases. To this
reaction mixture was added drop wise a solution of allyl bromide
(1.1 mmol) in dry DMF. The reaction mixture was heated to 60 C
with constant stirring for about 6 h. After the completion of the
reaction, as evident from TLC, quenching was done by drop wise
addition of water (20 mL) with subsequent extraction with ethyl
acetate (3  30 mL). The combined organic layers were washed
with brine solution, dried over anhydrous Na2SO4 and concentratedTable 2
Cytotoxicity of some active compounds against HCT116 (colon cancer cell line) cells.
Compound R n Cytotoxicity % inhibition
0.2 mM 2.0 mM 20 mM
11a H 1 0 2 91
11b Cl 1 0 11 88
11e H 2 2 12 85
11f Cl 2 0 2 46
11h F 2 2 12 66
11i H 3 0 5 37
11l F 3 1 0 83
Doxorubicin 84 79 79
Staurosporine 16 80 90
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column chromatography using hexane: ethyl acetate (4:1) mixture
furnished the desired N-allyl isatin derivatives in good yields.
3.2. Procedure for the synthesis of 1-oxiranylmethyl isatin 3
N-allyl isatin 2 was added to a stirred suspension of m-chlor-
operbenzoic acid (m-CPBA) (1.2 mmol) in dry CHCl3 at 0 C. The
reaction mixture was allowed to attain room temperature and
subsequently refluxed at 60 C for 2 h. After the completion of the
reaction as evident from TLC, the excess of m-CPBA was quenched
by treatment with a saturated solution of K2CO3 and the organic
layer was subsequently extracted with chloroform (3  30 mL). The
combined organic layers were dried over anhydrous Na2SO4 and
concentrated under reduced pressure resulting in the isolation of a
crude solid whichwas recrystallized using (9:1) hexane:chloroform
mixture.
3.3. General method for the preparation of isatin-4aminoquinoline
conjugates 11aep
To the stirred solution of 1-oxiranylmethyl isatin 3 (1 mmol) and
4-aminoquinoline 9 (1 mmol) in dry toluene was added catalytic
amount of p-toluene sulphonic acid. The reaction mixture was
refluxed at 110 C for 6 h and the progress was monitored by TLC.
On completion, water (15 mL) was added to the reaction mixture
and subsequently extraction was done using chloroform
(2  50 mL). Combined organic layers were dried over anhydrous
sodium sulphate and concentrated under reduce pressure. Purifi-
cation of reaction mixture via column chromatography using hex-
ane:ethylacetate (3:2) mixture as eluent resulted in the isolation of
desired hybrids 11aep.
3.3.1. 1-{2-[2-(7-Chloro-quinolin-4-ylamino)-ethylamino]-3-
hydroxy-propyl}-1H-indole-2,3-dione (11a)
White solid, yield 85%, m.p. 183e184 C; 1H NMR (300 MHz,
CDCl3): dH 3.48 (s, 2H, -CH2-); 3.80 (s, 4H, 2 eCH2e); 5.16e5.31
(m, 2H, eCH2e); 5.83e5.98 (m, 1H, eCHe); 6.34 (d, J ¼ 5.1 Hz, 1H,
H2); 6.56 (d, J ¼ 9.0 Hz, 1H, AreH); 7.16e7.31 (m, 3H, H4 þ 2AreH);
7.53 (s, 1H, AreH); 7.89 (s, 1H, H5); 7.96 (d, J ¼ 9.0 Hz, 1H, H3); 8.40
(d, J ¼ 5.1 Hz, 1H, H1); 13C NMR (75 MHz, CDCl3): dC 37.2, 42.5, 44.1,
99.7, 111.3, 114.3, 114.6, 115.2, 117.5, 123.3, 124.8, 125.7, 127.3, 128.2,
132.3, 134.6, 135.1, 148.9, 151.5, 169.9. HRMS calculated for
C22H21ClN4O3 424.1302 [Mþ] found 424.1309; Anal. Calcd (%) for: C,
62.19; H, 4.98; N, 13.19; found C, 62.26; H, 4.84; N, 13.27.
3.3.2. 5-Chloro-1-{2-[2-(7-Chloro-quinolin-4-ylamino)-
ethylamino]-3-hydroxy-propyl}-1H-indole-2,3-dione (11b)
White solid, yield 86%, m.p. 175e176 C; 1H NMR (300 MHz,
CDCl3): dH 3.29 (s, 2H, eCH2e); 3.58 (s, 4H, 2xeCH2e); 4.94e5.10
(m, 2H, -CH2-); 5.65e5.76 (m, 1H, -CH-); 6.22 (d, J¼ 5.1 Hz, 1H, H2);
6.34e6.39 (m, 1H, AreH); 6.95e7.15 (m, 3H, H4þ 2AreH); 7.24 (s,
1H, eNH exchangeable with D2O); 7.33e7.35 (m, 1H, AreH);
7.64e7.70 (m, 2H, H5þ eNH exchangeable with D2O); 7.83 (d,
J ¼ 8.8 Hz, 1H, H3); 8.20e8.24 (m, 2H, H1þ eOH exchangeable with
D2O); 13C NMR (75MHz, CDCl3): dC 37.5, 42.0, 44.7, 98.5,113.1, 115.4,
115.8, 117.0, 117.8, 123.9, 124.5, 126.0, 127.6, 131.8, 134.2, 134.8, 147.2,
147.7, 150.3, 151.0, 168.5. HRMS calculated for C22H20Cl2N4O3
458.0912 [Mþ] found 458.0921; Anal. Calcd (%) for: C, 57.53; H,
4.39; N, 12.20; found C, 57.45; H, 4.47; N, 12.28.
3.3.3. 1-{2-[2-(7-Chloro-quinolin-4-ylamino)-ethylamino]-3-
hydroxy-propyl}-5methyl-1H-indole-2,3-dione (11c)
White solid, yield 85%, m.p. 169e170 C; 1H NMR (300 MHz,
CDCl3): dH 2.29 (s, 3H, eCH3); 3.35 (s, 2H, eCH2e); 3.62 (s, 4H,eCH2e); 4.98e5.15 (m, 2H, eCH2e); 5.63e5.71 (m, 1H, eCHe);
6.25 (d, J ¼ 5.1 Hz, 1H, H2); 6.35e6.39 (m, 1H, AreH); 7.19 (dd,
J ¼ 2.4 Hz, 9.0 Hz, 1H, H4); 7.29e7.30 (m, 1H, AreH); 7.53 (s, 1H,
AreH); 7.67e7.77 (m, 2H, H5þ eNH exchangeable with D2O); 7.93
(d, J ¼ 9.0 Hz, 1H, H3); 8.18e8.21 (m, 2H, H1þ eOH exchangeable
with D2O); 13C NMR (75 MHz, CDCl3): dC 20.1, 37.6, 42.5, 44.9, 99.2,
111.9, 114.3, 114.6, 115.2, 123.9, 124.7, 125.6, 128.1, 132.4, 133.9, 134.6,
135.1, 147.5, 148.8, 150.7, 151.6, 169.8. HRMS calculated for
C23H23ClN4O3 438.1459 [Mþ] found 438.1451; Anal. Calcd (%) for: C,
62.94; H, 5.28; N, 12.77; found C, 62.85; H, 5.16; N, 12.85.
3.3.4. 1-{2-[2-(7-Chloro-quinolin-4-ylamino)-ethylamino]-3-
hydroxy-propyl}-5-fluoro-1H-indole-2,3-dione (11d)
White solid, yield 87%, m.p. 180e181 C; 1H NMR (300 MHz,
CDCl3): dH 3.31 (s, 2H, eCH2e); 3.61 (s, 4H, 2 eCH2e); 4.95e5.15
(m, 2H, eCH2e); 5.61e5.72 (m, 1H, eCHe); 6.27 (d, J ¼ 5.1 Hz, 1H,
H2); 6.35 (d, J ¼ 8.2 Hz, 1H, AreH); 7.18 (dd, J ¼ 2.4, 8.7 Hz, 1H, H4);
7.27 (d, J¼ 8.2,1H, AreH); 7.54 (s,1H, AreH); 7.65e7.73 (m, 2H, H5þ
eNH exchangeable with D2O); 7.92 (d, J ¼ 9.0 Hz, 1H, H4); 8.32 (d,
J ¼ 5.1 Hz, 1H, H1); 13C NMR (75 MHz, CDCl3): dC 38.1, 42.0, 45.2,
98.7, 113.3, 115.5, 115.6, 117.0, 117.9, 123.9, 124.3, 126.3, 127.6, 131.6,
134.2, 134.9, 147.3, 147.7, 150.4, 151.2, 168.7. HRMS calculated for
C22H20ClFN4O3 442.1208 [Mþ] found 442.1215; Anal. Calcd (%) for:
C, 59.66; H, 4.55; N, 12.65; found C, 59.74; H, 4.46; N, 12.57.
3.3.5. 1-{2-[3-(7-Chloro-quinolin-4-ylamino)-propylamino]-3-
hydroxy-propyl}-1H-indole-2,3-dione (11e)
White solid, yield 83%, m.p. 158e159 C; 1H NMR (300 MHz,
CDCl3): dH 1.94e2.01 (m, 2H, eCH2e); 3.48e3.49 (m, 2H, eCH2e);
3.55e3.60 (m, 2H, eCH2e); 3.81 (s, 2H, eCH2e); 5.17 (dd, J ¼ 1.4,
10.3 Hz, 1H, eCH2e); 5.30 (dd, J ¼ 1.4, 10.3 Hz, 1H, eCH2e);
5.91e5.98 (m, 1H, eCHe); 6.38 (d, J ¼ 6.0 Hz, 1H, H2); 6.56 (t,
J ¼ 7.2 Hz, 1H, AreH); 6.65 (d, J ¼ 8.3 Hz, 1H, AreH); 6.96 (t,
J ¼ 6.1 Hz, 1H, NH exchangeable with D2O); 7.26e7.32 (m, 2H,
H4 þ AreH); 7.44 (dd, J ¼ 0.9, 7.8 Hz, 1H, AreH); 7.58 (s, 1H, NH
exchangeable with D2O); 7.72 (s, 1H, OH exchangeable with D2O);
7.90 (d, J ¼ 1.7 Hz, 1H, H5); 8.10 (d, J ¼ 9.0 Hz, 1H, H3); 8.32 (d,
J ¼ 6.0 Hz, 1H, H1); 13C NMR (75 MHz, CDCl3): dC 28.2, 36.6, 39.9,
45.4, 98.1, 112.1, 114.5, 115.1, 116.0, 116.7, 122.9, 124.9, 126.1, 127.6,
133.1, 134.7, 136.6, 148.0, 149.5, 152.1, 171.0. HRMS calculated for
C23H23ClN4O3 438.1459 [Mþ] found 438.1451; Anal. Calcd (%) for: C,
62.94; H, 5.28; N, 12.77; found C, 62.83; H, 5.41; N, 12.68.
3.3.6. 5-Chloro-1-{2-[3-(7-Chloro-quinolin-4-ylamino)-
propylamino]-3-hydroxy-propyl}-1H-indole-2,3-dione (11f)
White solid, yield 85%, m.p. 151e152 C; 1H NMR (300 MHz,
CDCl3): dH 1.93e2.01 (m, 2H, eCH2e); 3.45e3.47 (m, 2H, eCH2e);
3.56e3.60 (m, 2H, eCH2e); 3.79 (s, 2H, eCH2e); 5.19 (dd, J ¼ 1.4,
10.3 Hz, 1H, eCH2e); 5.31 (dd, J ¼ 1.4, 10.3 Hz, 1H, eCH2e);
5.91e5.98 (m, 1H, eCHe); 6.39 (d, J ¼ 6.0 Hz, 1H, H2); 6.71 (d,
J ¼ 8.3 Hz, 1H, AreH); 6.93 (t, J ¼ 6.1 Hz, 1H, NH exchangeable with
D2O); 7.16e7.23 (m, 2H, AreH); 7.39 (d, J ¼ 9.0 Hz, 1H, H4); 7.58 (s,
1H, NH exchangeable with D2O); 7.75 (s, 1H, NH exchangeable with
D2O); 7.88 (d, J ¼ 9.0 Hz, 1H, H3); 7.99 (s, 1H, H5); 8.66 (d, J ¼ 6.0 Hz,
1H, H1); 13C NMR (75 MHz, CDCl3): dC 28.9, 35.9, 40.2, 46.1, 99.1,
111.2, 112.8, 115.3, 116.5, 122.4, 123.7, 124.6, 125.7, 127.1, 133.4, 134.1,
135.9, 147.8, 148.9, 150.2, 152.5, 169.3. HRMS calculated for
C23H22Cl2N4O3 472.1069 [Mþ] found 472.1075; Anal. Calcd (%) for: C,
58.36; H, 4.68; N, 11.84; found C, 58.27; H, 4.76; N, 11.93.
3.3.7. 1-{2-[3-(7-Chloro-quinolin-4-ylamino)-propylamino]-3-
hydroxy-propyl}-5-methyl-1H-indole-2,3-dione (11g)
White solid, yield 81%, m.p. 157e158 C; 1H NMR (300 MHz,
CDCl3): dH 1.92e2.00 (m, 2H, eCH2e); 2.29 (s, 3H, eCH3);
3.45e3.46 (m, 2H, eCH2e); 3.56e3.60 (m, 2H, eCH2e); 3.81 (s, 2H,
Nisha et al. / European Journal of Medicinal Chemistry 84 (2014) 566e573 571eCH2e); 5.19 (dd, J ¼ 1.4, 10.3 Hz, 1H, eCH2e); 5.30 (dd, J ¼ 1.4,
10.3 Hz, 1H, eCH2e); 5.91e5.97 (m, 1H, eCHe); 6.41 (d, J ¼ 6.0 Hz,
1H, H2); 6.71 (d, J ¼ 8.3 Hz, 1H, AreH); 7.16e7.27 (m, 2H, AreH);
7.39 (d, J ¼ 9.0 Hz, 1H, H4); 7.56 (s, 1H, NH exchangeable with D2O);
7.73 (s, 1H, NH exchangeable with D2O); 7.89 (d, J ¼ 9.0 Hz, 1H, H3);
7.97 (s, 1H, H5); 8.58 (d, J ¼ 6.0 Hz, 1H, H1); 13C NMR (75 MHz,
CDCl3): dC 20.9, 27.9, 36.3, 39.5, 45.9, 99.7, 111.7, 113.9, 115.7, 116.1,
117.2, 123.2, 123.9, 126.5, 127.1, 133.7, 134.2, 147.5, 147.9, 149.3, 150.9,
151.7, 168.9. HRMS calculated for C24H25ClN4O3 452.1615 [Mþ]
found 452.1608; Anal. Calcd (%) for: C, 63.64; H, 5.56; N, 12.37;
found C, 63.75; H, 5.43; N, 12.45.
3.3.8. 1-{2-[3-(7-Chloro-quinolin-4-ylamino)-propylamino]-3-
hydroxy-propyl}-5-fluoro-1H-indole-2,3-dione (11h)
White solid, yield 88%, m.p. 148e149 C; 1H NMR (300 MHz,
CDCl3): dH 1.94e2.00 (m, 2H, eCH2e); 3.45e3.47 (m, 2H, eCH2e);
3.56e3.60 (m, 2H, eCH2e); 3.83 (s, 2H, eCH2e); 5.17 (dd, J ¼ 1.4,
10.3 Hz, 1H, eCH2e); 5.30 (dd, J ¼ 1.4, 10.3 Hz, 1H, eCH2e);
5.92e5.98 (m, 1H, eCHe); 6.37 (d, J ¼ 6.0 Hz, 1H, H2); 6.67 (d,
J ¼ 8.3 Hz, 1H, AreH); 7.16e7.21 (m, 2H, AreH); 7.39 (d, J ¼ 9.0 Hz,
1H, H4); 7.56 (s, 1H, NH exchangeable with D2O); 7.73 (s, 1H, NH
exchangeable with D2O); 7.92 (d, J¼ 9.0 Hz,1H, H3); 8.12 (s, 1H, H5);
8.58 (d, J ¼ 6.0 Hz, 1H, H1); 13C NMR (75 MHz, CDCl3): dC 28.5, 36.9,
40.1, 45.7, 98.9, 113.1, 114.6, 115.8, 116.7, 122.1, 123.5, 124.9, 126.4,
127.6, 132.5, 135.1, 136.1, 147.5, 148.5, 150.5, 152.5, 171.3. HRMS
calculated for C23H22ClFN4O3 456.1364 [Mþ] found 456.1373; Anal.
Calcd (%) for: C, 60.46; H, 4.85; N, 12.26; found C, 60.59; H, 4.99; N,
12.17.s.
3.3.9. 1-{2-[4-(7-Chloro-quinolin-4-ylamino)-butylamino]-3-
hydroxy-propyl}-1H-indole-2,3-dione (11i)
White solid, yield 82%, m.p. 155e156 C; 1H NMR (300 MHz,
CDCl3): dH 1.63e1.76 (m, 4H, 2eCH2e); 3.34 (dd, J¼ 6.04, 12.0 Hz,
4H, 2 eCH2e); 3.77 (s, 2H, eCH2e); 5.11 (dd, J ¼ 1.4, 10.3 Hz, 1H,
eCH2e); 5.30 (dd, J ¼ 1.5, 17.2 Hz, 1H, eCH2e); 5.87e5.96 (m, 1H,
eCHe); 6.53e6.64 (m, 3H, H2þ 2AreH); 7.24 (t, J ¼ 8.2 Hz, 1H,
AreH); 7.49e7.54 (m, 2H, H4þ1AreH); 7.83 (d, J ¼ 1.8 Hz, 1H, H5);
7.94 (s, 2H, 2 NH exchangeable with D2O); 8.36e8.42 (m, 3H,
H3þH1þOH exchangeable with D2O); 13C NMR (75 MHz, CDCl3): dC
25.2, 26.6, 38.4, 42.3, 44.6, 98.5, 111.2, 114.2, 115.2, 115.3, 116.9,
124.5, 124.7, 125.1, 128.2, 132.1, 134.6, 135.5, 146.2, 148.9, 149.4,
151.4, 169.1. HRMS calculated for C24H25ClN4O3 452.1615 [Mþ]
found 452.1607; Anal. Calcd (%) for: C, 63.64; H, 5.56; N, 12.37;
found C, 63.78; H, 5.69; N, 12.48.
3.3.10. 5-Chloro-1-{2-[4-(7-Chloro-quinolin-4-ylamino)-
butylamino]-3-hydroxy-propyl}-1H-indole-2,3-dione (11j)
Pale yellow solid, yield 82%, m.p. 160e161 C; 1H NMR
(300 MHz, CDCl3): dH 1.65e1.77 (m, 4H, 2x eCH2e); 3.32 (d,
J¼ 5.76 Hz, 2H,eCH2e); 3.35 (d, J¼ 5.7 Hz, 2H,eCH2e); 3.78 (s, 2H,
eCH2e); 5.13 (dd, J ¼ 1.4, 10.3 Hz, 1H, eCH2e); 5.29 (dd, J ¼ 1.5,
17.2 Hz, 1H, eCH2e); 5.84e5.95 (m, 1H, eCHe); 6.51 (d, J ¼ 6.0 Hz,
1H, H2); 6.64 (d, J ¼ 8.3 Hz, 1H, AreH); 7.15e7.27 (m, 2H, ArH); 7.35
(d, J ¼ 9.0 Hz, 1H, H4); 7.69 (s, 1H, NH exchangeable with D2O); 7.85
(d, J¼ 9.0 Hz,1H, H3); 7.91 (s,1H, H5); 8.62 (d, J¼ 6.0 Hz,1H, H1); 13C
NMR (75 MHz, CDCl3): dC 25.6, 26.9, 37.9, 42.7, 44.1, 99.1, 112.8,
113.7, 114.9, 115.7, 116.1, 124.6, 126.3, 127.3, 128.6, 133.3, 133.9, 135.1,
147.4, 148.5, 150.1, 151.9, 170.1. HRMS calculated for C24H24Cl2N4O3
486.1225 [Mþ] found 486.1232; Anal. Calcd (%) for: C, 59.14; H, 4.96;
N, 11.50; found C, 59.27; H, 4.83; N, 11.43.
3.3.11. 1-{2-[4-(7-Chloro-quinolin-4-ylamino)-butylamino]-3-
hydroxy-propyl}-5-methyl-1H-indole-2,3-dione (11k)
White solid, yield 83%, m.p. 145e146 C; 1H NMR (300 MHz,
CDCl3): dH 1.62e1.73 (m, 4H, 2x eCH2e); 2.29 (s, 3H, eCH3);2.51e2.56 (m, 2H, eCH2e); 3.33 (d, J ¼ 5.7 Hz, 2H, eCH2e); 3.34 (d,
J ¼ 5.7 Hz, 2H, eCH2e); 3.76 (s, 2H, eCH2e); 5.15 (dd, J ¼ 1.4,
10.3 Hz, 1H, eCH2e); 5.27 (dd, J ¼ 1.4, 10.3 Hz, 1H, eCH2e);
5.84e5.93 (m, 1H, eCHe); 6.51 (d, J ¼ 6.0 Hz, 1H, H2); 6.59 (d,
J ¼ 8.3 Hz, 1H, AreH); 7.13e7.24 (m, 2H, AreH); 7.39 (d, J ¼ 9.0 Hz,
1H, H4); 7.63 (s, 1H, NH exchangeable with D2O); 7.81 (d, J ¼ 9.0 Hz,
1H, H3); 7.91 (s, 1H, H5); 8.67 (d, J ¼ 6.0 Hz, 1H, H1); 13C NMR
(75MHz, CDCl3): dC 20.9, 25.9, 27.1, 38.8, 42.4, 45.1, 98.9,111.9,114.5,
115.2,115.8,116.5,123.8,124.9,125.5,127.6,132.5,134.1,135.4, 146.7,
148.8, 149.7, 151.1, 169.7. HRMS calculated for C25H27ClN4O3
466.1772 [Mþ] found 466.1766; Anal. Calcd (%) for: C, 64.30; H, 5.83;
N, 12.00; found C, 64.43; H, 5.91; N, 12.11.
3.3.12. 1-{2-[4-(7-Chloro-quinolin-4-ylamino)-butylamino]-3-
hydroxy-propyl}-5-fluoro-1H-indole-2,3-dione (11l)
White solid, yield 82%, m.p. 148e149 C; 1H NMR (300 MHz,
CDCl3): dH 1.67e1.75 (m, 4H, 2x eCH2e); 2.53e2.57 (m, 2H,
eCH2e); 3.32 (d, J ¼ 5.7 Hz, 2H, eCH2e); 3.34 (d, J ¼ 5.7 Hz, 2H,
eCH2e); 3.75 (s, 2H,eCH2e); 5.14 (dd, J¼ 1.4, 10.3 Hz, 1H,eCH2e);
5.23 (dd, J ¼ 1.5, 17.2 Hz, 1H, eCH2e); 5.82e5.93 (m, 1H, eCHe);
6.51e6.60 (m, 3H, H2þ 2AreH); 7.33 (d, J¼ 9.0 Hz,1H, H4); 7.49 (dd,
J ¼ 0.9, 7.8 Hz, 1H, AreH); 7.88 (d, J ¼ 1.8 Hz, 1H, H5); 7.95 (s, 2H,
H3þ NH exchangeable with D2O); 8.65 (d, J ¼ 6.0 Hz, 1H, H1); 13C
NMR (75 MHz, CDCl3): dC 25.2, 26.7, 38.5, 41.9, 44.2, 98.4, 113.1,
114.5,115.1,115.3, 116.7, 124.5, 124.6,125.3,128.3,132.5,134.6,135.5,
146.1, 148.8, 149.2, 151.3, 169.1. HRMS calculated for C24H24ClFN4O3
470.1521 [Mþ] found 470.1529; Anal. Calcd (%) for: C, 61.21; H, 5.14;
N, 11.90; found C, 61.36; H, 5.29; N, 11.81.
3.3.13. 1-{2-[6-(7-Chloro-quinolin-4-ylamino)-hexylamino]-3-
hydroxy-propyl}-1H-indole-2,3-dione (11m)
White solid, yield 79%, m.p. 165e166 C; 1H NMR (300 MHz,
CDCl3): dH 1.27e1.31 (m, 4H, eCH2e); 1.91e1.97 (m, 2H, eCH2e);
2.52e2.55 (m, 2H, eCH2e); 3.31 (dd, J ¼ 6.1, 12.1 Hz, 2H, eCH2e);
3.35 (dd, J¼ 6.3, 12.1 Hz, 2H,eCH2e); 3.75 (s, 2H,eCH2e); 5.12 (dd,
J ¼ 1.4, 10.3 Hz, 1H, eCH2e); 5.31 (dd, J ¼ 1.5, 17.2 Hz, 1H, eCH2e);
5.85e5.94 (m, 1H, eCHe); 6.36 (d, J ¼ 6.0 Hz, 1H, H2); 6.63 (d,
J ¼ 8.3 Hz, 1H, AreH); 6.96 (t, J ¼ 8.1 Hz, 1H, AreH); 7.23e7.29 (m,
2H, H4 þ AreH); 7.48 (dd, J ¼ 0.9, 7.8 Hz, 1H, AreH); 7.55 (s, 1H, NH
exchangeable with D2O); 7.74 (s, 1H, NH exchangeable with D2O);
7.91 (d, J ¼ 1.7 Hz, 1H, H5); 8.10 (d, J ¼ 9.0 Hz, 1H, H3); 8.31 (d,
J ¼ 6.0 Hz, 1H, H1); 13C NMR (75 MHz, CDCl3): dC 28.2, 28.5, 31.9,
32.7, 36.6, 39.9, 45.5, 98.7, 112.5, 114.1, 115.8, 116.1, 116.3, 122.9,
123.4,126.2,127.5,133.2,134.7,136.6,148.1,149.5,152.1,171.1. HRMS
calculated for C26H29ClN4O3 480.1928 [Mþ] found 480.1935; Anal.
Calcd (%) for: C, 64.92; H, 6.08; N, 11.65; found C, 64.86; H, 6.19; N,
11.53.
3.3.14. 5-Chloro-1-{2-[6-(7-Chloro-quinolin-4-ylamino)-
hexylamino]-3-hydroxy-propyl}-1H-indole-2,3-dione (11n)
White solid, yield 80%, m.p. 153e154 C; 1H NMR (300 MHz,
CDCl3): dH 1.28e1.32 (m, 4H, eCH2e); 1.93e1.97 (m, 2H, eCH2e);
2.52e2.56 (m, 2H, eCH2e); 3.34 (dd, J ¼ 5.7 Hz, 12.0 Hz, 2H,
eCH2e); 3.36 (dd, J¼ 5.7, 12.1 Hz, 2H,eCH2e); 3.75 (s, 2H,eCH2e);
5.13 (dd, J ¼ 1.4, 10.3 Hz, 1H, eCH2e); 5.31 (dd, J ¼ 1.5, 17.2 Hz, 1H,
eCH2e); 5.83e5.95 (m,1H,eCHe); 6.35 (d, J¼ 6.0 Hz, 1H, H2); 6.63
(d, J ¼ 8.3 Hz, 1H, AreH); 7.37 (d, J ¼ 9.0 Hz, 1H, H4); 7.43e7.49 (m,
2H, 2AreH); 7.53 (s, 1H, NH exchangeable with D2O); 7.74 (s, 1H, NH
exchangeable with D2O); 7.92 (d, J ¼ 1.76 Hz, 1H, H5); 8.10 (d,
J ¼ 9.04 Hz, 1H, H3); 8.32 (d, J ¼ 6.0 Hz, 1H, H1); 13C NMR (75 MHz,
CDCl3): dC 28.4, 29.1, 31.5, 33.1, 36.8, 39.4, 45.7, 99.1, 111.5, 113.7,
115.3, 116.5, 117.2, 117.8, 122.5, 123.7, 126.7, 127.8, 133.5, 134.1, 147.3,
148.2, 150.3, 152.5, 169.3. HRMS calculated for C26H28Cl2N4O3
514.1538 [Mþ] found 514.1545; Anal. Calcd (%) for: C, 60.59; H, 5.48;
N, 10.87; found C, 60.43; H, 5.59; N, 10.74.
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hydroxy-propyl}-5-methyl-1H-indole-2,3-dione (11o)
White solid, yield 85%, m.p. 155e156 C; 1H NMR (300 MHz,
CDCl3): dH 1.25e1.30 (m, 4H, 2 eCH2); 1.87e1.95 (m, 2H, eCH2e);
2.28 (s, 3H, eCH3); 2.58e2.63 (m, 2H, eCH2e); 3.31 (dd, J ¼ 5.8,
12.1 Hz, 2H, eCH2e); 3.35 (dd, J ¼ 5.7, 12.1 Hz, 2H, eCH2e); 3.87 (s,
2H, eCH2e); 5.07 (dd, J ¼ 1.4, 10.3 Hz, 1H, eCH2e); 5.28 (dd,
J ¼ 1.5, 17.2 Hz, 1H, eCH2e); 5.65e5.76 (m, 1H, eCHe); 6.25 (d,
J ¼ 6.0 Hz, 1H, H2); 6.54 (d, J ¼ 8.3 Hz, 1H, AreH); 6.98 (d,
J ¼ 9.0 Hz, 1H, H4); 7.37e7.41 (m, 2H, 2AreH); 7.40 (s, 1H, NH
exchangeable with D2O); 7.81 (s, 1H, NH exchangeable with D2O);
7.89 (d, J ¼ 1.7 Hz, 1H, H5); 8.13 (d, J ¼ 9.0 Hz, 1H, H3); 8.32 (d,
J ¼ 6.0 Hz, 1H, H1); 13C NMR (75 MHz, CDCl3): dC 21.5, 27.9, 28.6,
31.1, 33.3, 36.2, 40.0, 46.0, 98.9, 112.3, 114.9, 115.7, 116.4, 117.3, 122.1,
124.5, 125.8, 127.1, 133.9, 135.2, 136.9, 147.2, 148.7, 151.3, 152.1,
170.0. HRMS calculated for C27H31ClN4O3 494.2085 [Mþ] found
494.2077; Anal. Calcd (%) for: C, 65.51; H, 6.31; N, 11.32; found C,
65.67; H, 6.42; N, 11.43.
3.3.16. 1-{2-[6-(7-Chloro-quinolin-4-ylamino)-hexylamino]-3-
hydroxy-propyl}-5-fluoro-1H-indole-2,3-dione (11p)
White solid, yield 87%, m.p. 152e153 C; 1H NMR (300 MHz,
CDCl3): dH 1.28e1.34 (m, 4H, 2 eCH2e); 1.91e1.95 (m, 2H,
eCH2e); 2.48e2.52 (m, 2H, eCH2e); 3.41 (dd, J ¼ 5.8, 12.1 Hz, 2H,
eCH2e); 3.47 (dd, J ¼ 5.8, 12.1 Hz, 2H, eCH2e); 3.78 (s, 2H,
eCH2e); 5.11e5.32 (m, 2H, eCH2e); 5.91e5.98 (m, 1H, eCHe);
6.41 (d, J ¼ 6.0 Hz, 1H, H2); 6.69 (d, J ¼ 8.3 Hz, 1H, AreH); 7.31 (d,
J ¼ 9.0 Hz, 1H, H4); 7.38e7.43 (m, 2H, 2AreH); 7.52 (s, 1H, -NH
exchangeable with D2O); 7.67 (s, 1H, -NH exchangeable with D2O);
7.98 (d, J ¼ 1.8 Hz, 1H, H5); 8.17 (d, J ¼ 9.0 Hz, 1H, H3); 8.33 (d,
J ¼ 6.0 Hz, 1H, H1); 13C NMR (75 MHz, CDCl3): dC 28.3, 28.5, 31.7,
32.6, 36.9, 40.1, 45.1, 98.1, 112.1, 114.3, 115.7, 116.1, 116.9, 122.4,
124.3, 126.8, 127.9, 133.2, 134.5, 136.6, 148.4, 149.6, 150.6, 152.2,
171.2. HRMS calculated for C26H28ClFN4O3 498.1834 [Mþ] found
498.1829; Anal. Calcd (%) for: C, 62.58; H, 5.66; N, 11.23; found C,
62.67; H, 5.75; N, 11.34.
3.4. General method for the preparation of isatin-4-piperazin-1-yl-
quinoline conjugates 12aed
The stirred solution of 1-Oxiranylmethyl isatin 3 (1 mmol), 4-
piperazin-1-yl-quinoline 10 (1 mmol) and catalytic amount of p-
toluene sulphonic acid in dry toluene was refluxed at 110 C for
12 h. On completion of the reaction, as monitored by TLC, water
(15 mL) was added to the reaction mixture and extracted with
chloroform (2  30 mL). Combined organic layers were dried over
anhydrous sodium sulphate and concentrated under reduce pres-
sure. Purification of reaction mixture thus obtained via column
chromatography using hexane:ethylacetate (3:2) mixture as eluent
resulted in the isolation of desired chimeras 12aed.
3.4.1. 1-{2-[4-(7-Chloro-quinolin-4-yl)-piperazin-1-yl]-3-hydroxy-
propyl}-1H-indole-2,3-dione (12a)
White solid, yield 87%, m.p. 121e122 C; 1H NMR (300 MHz,
CDCl3): dH 2.75 (s, 4H, 2x eCH2e); 3.18 (s, 4H, 2x eCH2e); 3.28 (s,
2H, eCH2e); 4.95e5.13 (m, 2H, eCH2e); 5.85e5.97 (m, 1H, eCHe);
6.35 (d, J ¼ 5.1 Hz, 1H, H2); 6.53e6.59 (m, 1H, AreH); 7.17 (dd,
J ¼ 2.4 Hz, 8.7 Hz, 1H, H4); 7.28e7.30 (m, 1H, AreH); 7.47e7.53 (m,
1H, AreH); 7.89 (d, J ¼ 2.4 Hz, 1H, H5); 7.96 (d, J ¼ 9.0 Hz, 1H, H3);
8.41 (d, J ¼ 5.1 Hz, 1H, H1); 13C NMR (75 MHz, CDCl3): dC 45.7, 53.1,
58.9, 98.1, 112.5, 114.4, 115.6, 116.2, 116.9, 122.8, 124.9, 126.2, 127.6,
133.2, 134.6, 136.5, 148.2, 149.6, 152.2, 171.1. HRMS calculated for
C24H23ClN4O3 450.1459 [Mþ] found 450.1465; Anal. Calcd (%) for: C,
63.93; H, 5.14; N, 12.43; found C, 63.87; H, 5.27; N, 12.51.3.4.2. 5-Chloro-1-{2-[4-(7-Chloro-quinolin-4-yl)-piperazin-1-yl]-
3-hydroxy-propyl}-1H-indole-2,3-dione (12b)
Pale yellow solid, yield 82%, m.p. 117e118 C; 1H NMR (300MHz,
CDCl3): dH 2.76 (s, 4H, 2x eCH2e); 3.15 (s, 4H, 2x eCH2e); 3.30 (s,
2H, eCH2e); 4.96e5.15 (m, 2H, eCH2e); 5.87e5.99 (m, 1H, eCHe);
6.25 (d, J ¼ 5.1 Hz, 1H, H2); 6.32e6.37 (m, 1H, AreH); 7.13e7.24 (m,
2H, 2AreH); 7.34 (d, J¼ 9.0 Hz,1H, H4); 7.64e7.73 (m, 2H, H5þeOH
exchangeable with D2O); 7.82 (d, J ¼ 8.8 Hz, 1H, H3); 8.17e8.25 (m,
2H, H1þ eOH exchangeable with D2O); 13C NMR (75 MHz, CDCl3):
dC 45.5, 54.1, 58.2, 99.1, 111.7, 113.2, 114.8, 115.1, 116.5, 117.7, 123.6,
124.3, 125.4, 127.3, 133.7, 136.1, 147.5, 148.7, 150.1, 152.5,169.1. HRMS
calculated for C24H22Cl2N4O3 484.1069 [Mþ] found 484.1060; Anal.
Calcd (%) for: C, 59.39; H, 4.57; N, 11.54; found C, 59.47; H, 4.69; N,
11.42.
3.4.3. 1-{2-[4-(7-Chloro-quinolin-4-yl)-piperazin-1-yl]-3-hydroxy-
propyl}-5-methyl-1H-indole-2,3-dione (12c)
Pale yellow solid, yield 82%, m.p.119e120 C; 1H NMR (300MHz,
CDCl3): dH 2.29 (s, 3H,eCH3); 2.76 (s, 4H, 2xeCH2e); 3.18 (s, 4H, 2x
eCH2e); 3.29 (s, 2H, eCH2e); 4.95e5.15 (m, 2H, eCH2e);
5.85e5.96 (m,1H,eCHe); 6.22 (d, J¼ 5.1 Hz,1H, H2); 6.34e6.37 (m,
1H, AreH); 7.11e7.16 (m, 1H, AreH); 7.25 (s, 1H, AreH); 7.39 (d,
J ¼ 9.0 Hz, 1H, H4); 7.98 (s, 1H, H5); 7.82 (d, J ¼ 9.0 Hz, 1H, H3);
8.19e8.22 (m, 2H, H1þ eOH exchangeable with D2O); 13C NMR
(75 MHz, CDCl3): dC 19.8, 46.1, 53.8, 57.4, 98.7, 112.8, 114.3, 116.5,
122.8, 124.9, 125.2, 125.9, 127.7, 132.8, 134.1, 135.8, 147.9, 148.2,
149.2, 151.7, 152.1, 171.2. HRMS calculated for C25H25ClN4O3
464.1615 [Mþ] found 464.1608; Anal. Calcd (%) for: C, 64.58; H, 5.42;
N, 12.05; found C, 64.65; H, 5.59; N, 12.18.
3.4.4. 1-{2-[4-(7-Chloro-quinolin-4-yl)-piperazin-1-yl]-3-hydroxy-
propyl}-5-fluoro-1H-indole-2,3-dione (12d)
Pale yellow solid, yield 79%, m.p.131e132 C; 1H NMR (300MHz,
CDCl3): dH 2.75 (s, 4H, 2x eCH2e); 3.17 (s, 4H, 2xeCH2e); 3.29 (s,
2H, eCH2e); 4.96e5.14 (m, 2H, eCH2e); 5.87e5.97 (m, 1H, eCHe);
6.29 (d, J ¼ 5.1 Hz, 1H, H2); 6.43e6.50 (m, 1H, AreH); 7.19e7.21 (m,
1H, AreH); 7.24e7.31 (m, 1H, AreH); 7.41 (d, J ¼ 9.0 Hz, 1H, H4);
7.64 (s, 1H, H5); 7.93 (d, J ¼ 8.8 Hz, 1H, H3); 8.35e8.40 (m, 2H, H1þ
eOH exchangeable with D2O); 13C NMR (75 MHz, CDCl3): dC 45.2,
53.8, 58.3, 99.3, 113.1, 114.2, 115.9, 116.5, 117.1, 123.8, 124.7, 126.9,
127.1, 133.6, 134.9, 136.1, 147.3, 148.4, 150.6, 152.8, 169.3. HRMS
calculated for C24H22ClFN4O3 468.1364 [Mþ] found 468.1372; Anal.
Calcd (%) for: C, 61.47; H, 4.73; N, 11.95; found C, 61.58; H, 4.65; N,
11.83.
3.5. Methods for assessment of antimalarial activity of test
compounds
The W2 strain of P. falciparum was cultured in RPMI-1640 me-
dium with 10% human serum, following standard methods, and
parasites were synchronized with 5% D-sorbitol [50]. Beginning at
the ring stage, microwell cultures were incubated with different
concentrations of compounds for 48 h. The compounds were added
fromDMSO stocks; the maximum concentration of DMSO used was
0.1%. Controls without inhibitors included 0.1% DMSO. After 48 h,
when control cultures had progressed to new rings, the culture
medium was removed, and cultures were incubated for 48 h with
1% formaldehyde in PBS, pH 7.4, at room temperature. Fixed para-
sites were then transferred to 0.1% Triton X-100 in PBS containing
1 nM YOYO-1 dye (Molecular Probes). Parasitaemia was deter-
mined from dot plots (forward scatter vs. fluorescence) acquired on
a FACSort flow cytometer using Cell Quest software (Beckton
Dickinson). IC50 values for growth inhibitionwere determined from
plots of percent control parasitaemia over inhibitor concentration
Nisha et al. / European Journal of Medicinal Chemistry 84 (2014) 566e573 573using the Prism 3.0 program, (GraphPad Software), with data from
duplicate experiments fitted by nonlinear regression [51].
3.6. In vitro cytotoxic studies
HCT116 (colon cancer cell line) cells were cultured in DMEM
supplemented with 10% FBS. Cells were plated in 96 well tissue
culture plates and treated with compound at three concentrations-
20 mM, 2 mM, 0.2 mM for 48 h 10 ml MTT 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide 5 mg/ml in PBS was added to
the wells. Plates were incubated for 4 h. Plates were centrifuged at
1000 rpm for 5 min. Supernatant was removed. 100 ml DMSO was
added to each well and mixed on shaker for 30 min. Absorbance
was measured at 550 nm in Envision Multilabel Plate Reader
(Perkin Elmer). Staurosporine and Doxorubicin were used as posi-
tive control. Percentage inhibition was calculated from absorbance
using DMSO control as 100%.
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